Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
15,213 questions in 2,394 reviews
current versionsNo studies 15,213 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Short protocol vs stop short protocol Live birth and ongoing pregnancies per woman randomised · women undergoing pituitary suppression in assisted reproduction Gonadotrophin‐releasing hormone agonist protocols for pituitary suppression in assisted reproduction (2015) · Cochrane | no estimate extracted | NR | No studies |
Short vs ultrashort protocol Live birth and ongoing pregnancies per woman randomised · women undergoing pituitary suppression in assisted reproduction Gonadotrophin‐releasing hormone agonist protocols for pituitary suppression in assisted reproduction (2015) · Cochrane | no estimate extracted | NR | No studies |
Caffeinated (experimental group) vs decaffeinated group (control group) Low birthweight · Pregnant women recruited before 20 weeks' gestation Effects of restricted caffeine intake by mother on fetal, neonatal and pregnancy outcomes (2015) · Cochrane | no estimate extracted | NR | No studies |
Caffeinated (experimental group) vs decaffeinated group (control group) Perinatal mortality rate · Pregnant women recruited before 20 weeks' gestation Effects of restricted caffeine intake by mother on fetal, neonatal and pregnancy outcomes (2015) · Cochrane | no estimate extracted | NR | No studies |
Caffeinated (experimental group) vs decaffeinated group (control group) Sudden infant death syndrome · Pregnant women recruited before 20 weeks' gestation Effects of restricted caffeine intake by mother on fetal, neonatal and pregnancy outcomes (2015) · Cochrane | no estimate extracted | NR | No studies |
Caffeinated (experimental group) vs decaffeinated group (control group) Gestational diabetes · Pregnant women recruited before 20 weeks' gestation Effects of restricted caffeine intake by mother on fetal, neonatal and pregnancy outcomes (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Medicine use · vulnerable and general populations Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Overall healthcare utilisation · vulnerable and general populations Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Health outcomes · vulnerable and general populations Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Medicine use · vulnerable population: senior 65 years of age or older Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Cost · vulnerable population: senior 65 years of age or older Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Insurer perspective (expenditures on medicines) · vulnerable population: senior 65 years of age or older Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Insurer perspective (expenditures on health care) · vulnerable population: senior 65 years of age or older Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Healthcare utilisation · vulnerable population: senior 65 years of age or older Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Overall healthcare utilisation · vulnerable population: senior 65 years of age or older Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Emergency department and hospitalisation · vulnerable population: senior 65 years of age or older Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Outpatient care · vulnerable population: senior 65 years of age or older Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Health outcomes · vulnerable population: senior 65 years of age or older Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Medicine use · seniors and general population Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Cost · seniors and general population Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Patient perspective · seniors and general population Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Insurer perspective (expenditures on health care) · seniors and general population Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Healthcare utilisation · seniors and general population Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Overall healthcare utilisation · seniors and general population Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Emergency department and hospitalisation · seniors and general population Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Outpatient care · seniors and general population Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Health outcome · seniors and general population Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Use of medicines for asymptomatic conditions · vulnerable and general populations Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Medicine use · vulnerable population (retirees and low income) Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Cost · vulnerable population (retirees and low income) Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Patient perspective · vulnerable population (retirees and low income) Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Insurer perspective (expenditures on medicines) · vulnerable population (retirees and low income) Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Insurer perspective (expenditures on health care) · vulnerable population (retirees and low income) Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Healthcare utilisation · vulnerable population (retirees and low income) Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Overall healthcare utilisation · vulnerable population (retirees and low income) Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Cost · vulnerable and general populations Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Health outcomes · vulnerable population (retirees and low income) Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Medicine use · low‐income/general population Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Cost · low‐income/general population Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Patient perspective · low‐income/general population Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Patient perspective · vulnerable and general populations Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Insurer perspective (expenditures on health care) · low‐income/general population Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Healthcare utilisation · low‐income/general population Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Overall healthcare utilisation · low‐income/general population Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Health outcomes · low‐income/general population Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Medicine use · general population Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Cost · general population Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Patient perspective · general population Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Insurer perspective (expenditures on health care) · general population Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Healthcare utilisation · general population Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |